TIDMANA
Ananda Developments PLC
25 August 2023
ANANDA DEVELOPMENTS PLC
Cannabinoid Medicine Research Roundup
Issue Twenty -One
Ananda's ambition is to be a leading provider of high-quality
cannabinoid medicines for the treatment of complex, chronic
inflammatory pain conditions in the UK and for international
markets.
Summary:
We have now renamed this document the Cannabinoid Medicine
Research Roundup. Over time we are seeing research become more
targeted into mechanisms, pathways and individual cannabinoids in
the attempt to understand how cannabis and/or its constituents work
- individually and together. As we continue to develop our
pharmaceutical grade cannabinoid medicines and the evidence needed
for the NHS and other countries' medical systems to prescribe them,
we believe that it is important to frame the conversation in the
appropriate terms.
Since our last issue in June 2023 we have seen papers dealing
with in vitro, in vivo and clinical evidence in areas as
wide-ranging as the positive activity of the Endocannabinoid System
and/or cannabidiol (CBD) in the clinic in untreated hypertension
and in vivo of axon regeneration following injury, more evidence in
epilepsy, and an in vitro acne model demonstrating the positive
effect of CBD. See links to these articles at the bottom of this
issue.
For this edition we have summarised three particularly
interesting articles in further detail. If you are taking tamoxifen
or know someone with sickle cell disease then you should be
particularly interested. We also look at the role of CBD in aging -
as if the rest of CBD's activities were not enough... it just might
help you live longer!
CBD-oil as a potential solution in case of severe
tamoxifen-related side effects
https://www.nature.com/articles/s41523-023-00570-x
Tamoxifen is effective in the treatment of estrogen-receptor
positive breast cancer and is recommended for two to three years
for postmenopausal patients and up to ten years for premenopausal
patients.
Unfortunately, tamoxifen can lead to bothersome side effects
such as hot flashes, arthralgia, insomnia, and mood alterations.
Forty percent of patients eventually discontinue tamoxifen therapy
early, mainly due to side effects.
In this open label trial of 26 patients taking tamoxifen and
tamoxifen + CBD, over 50 percent of the patients saw an improvement
in the side effect symptoms compared to baseline.
The most common side effects which was also where most of the
improvement was included hot flashes, joint pain, insomnia, sweats
and mood swings.
The role of CBD in aging
https://www.sciencedirect.com/science/article/pii/S075333222300865X
Aging is a very complex biological process. Current research
shows that there are at least 14 cellular and molecular hallmarks
of aging: deregulated nutrient sensing, mitochondrial dysfunction,
cellular senescence, compromised autophagy, inflammation,
disturbance of the microbiome, etc.
Multiple biological processes are involved in aging, such as
oxidative stress, inflammation, autophagy, proteostasis, cellular
senescence and DNA damage. Here, this article highlighted the
particular effect of CBD on oxidative stress, inflammation and
autophagy and clarified its antiaging mechanism.
CBD changed the life of this boy with sickle cell disease
https://onlinelibrary.wiley.com/doi/10.1002/ajh.27049
Patients with sickle cell disease (SCD) suffer from both acute
and chronic pain, whose pathophysiology involves not only red blood
cell sickling with subsequent vaso-occlusion leading to ischemia
reperfusion injury, but also neurogenic inflammation, possibly
mediated by mast cell activation.
Chronic pain affects approximately 40 percent of patients with
SCD, and its management is often a difficult challenge for
clinicians. Indeed, morphine, which has long been considered
the
reference analgesic for acute pain, may paradoxically worsen
chronic pain, by promoting mast cell activation and degranulation,
leading to the release of mast cell mediators such as substance P
or histamine.
This 15-year-old man with SCD had a history of 5 to 10
hospitalisations per year - two of these were for 56 and 49 days
because of the inefficacy of conventional analgesics, including
intravenous paracetamol, nalbuphine, morphine (PCA), nefopam,
ketamine, and amitriptyline.
The patient suffered from daily chronic pain in the lumbar
spine, thorax, and right knee, described as intense and permanent
with overlying cutaneous hyperesthesia and intermittent tingling
sensation. He was later started at 3 mg/kg of CBD per day gradually
increasing over a month to 22 mg/kg/day in 3 doses.
Two weeks were enough to observe a complete regression of pain
in the lumbar spine, thorax, and right knee. The patient
discontinued CBD one month after introduction due to supply
disruption, which caused recurrence of pain in the lumbar spine,
thorax, and right knee after one week.
Resumption of treatment at the same dose allowed further
regression of pain within one week. Since the beginning of CBD
treatment, the patient has not required further hospitalization for
VOC, with a follow-up of 10 months.
Additional articles
The Influence of Oral Cannabidiol on 24-h Ambulatory Blood
Pressure and Arterial Stiffness in Untreated Hypertension: A
Double-Blind, Placebo-Controlled, Cross-Over Pilot Study
https://link.springer.com/article/10.1007/s12325-023-02560-8
Injury-induced activation of the endocannabinoid system promotes
axon regeneration
https://www.cell.com/iscience/fulltext/S2589-0042(23)00891-X?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS258900422300891X%3Fshowall%3Dtrue
Real-world experience with cannabidiol as add-on treatment in
drug-resistant epilepsy
https://www.seizure-journal.com/article/S1059-1311(23)00193-0/fulltext
In vitro acne disease model from inertial focusing effect for
studying the interactions between sebocyte glands and
macrophages.
https://europepmc.org/article/med/37477791
The Directors of the Company accept responsibility for the
contents of this announcement.
ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497
ir@anandadevelopments.com
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE LLP +44 (0)20 3470 0470
Corporate Finance
Richard Morrison
Harry Davies-Ball
Corporate Broking
Abigail Wayne
Rob Rees
About Ananda Developments
Ananda is an AQSE-listed company whose ambition is to be a
leading provider of cannabinoid-based medicines for the treatment
of complex, chronic inflammatory pain conditions.
For more information, please visit:
https://anandadevelopments.com/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABELFLXVLEBBK
(END) Dow Jones Newswires
August 25, 2023 07:01 ET (11:01 GMT)
Ananda Developments (AQSE:ANA)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Ananda Developments (AQSE:ANA)
Historical Stock Chart
Von Mai 2023 bis Mai 2024